Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27169477 | 0.80 | PARP1 (0.65) | PARP1PARP2TNKSPARP6PARP3 | |
| SCHEMBL29397527 | 0.80 | PARP1 (0.65) | PARP1PARP2TNKSPARP6PARP3 | |
| Hydrochloric Acid SCHEMBL30053682 | 0.79 | PARP1 (0.64) | PARP1PARP2TNKSPARP6PARP3 | |
| Hydrochloric Acid SCHEMBL31312822 | 0.79 | PARP1 (0.64) | PARP1PARP2TNKSPARP6PARP3 | |
| Hydrochloric Acid SCHEMBL27169435 | 0.79 | PARP1 (0.64) | PARP1PARP2TNKSPARP6PARP3 | |
| SCHEMBL30663278 | 0.78 | PARP1 (0.65) | PARP1PARP2 | |
| SCHEMBL28869893 | 0.74 | MAPKAPK2 (0.39) | PARP1 | |
| SCHEMBL30010831 | 0.74 | PDE3B (0.44) | PARP1 | |
| SCHEMBL30011367 | 0.74 | MAPKAPK2 (0.39) | PARP1 | |
| SCHEMBL28869879 | 0.74 | PDE3B (0.44) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | PARP1 1119/4885PARP2 2032/4885PTPN11 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.